FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
Author(s)
Dennis M. Meletiche, PharmD, Director1, Chris Kozma, RPh, PhD, Independent Consultant and Adjunct Professor2, Michael Dickson, PhD, Professor31EMD Serono, Inc, Rockland, MA, USA; 2 University of South Carolina, West Columbia, SC, USA; 3 University of South Carolina, Columbia, SC, USA
OBJECTIVES Early initiation of therapy with disease-modifying drugs (DMDs) is important for the successful management of multiple sclerosis (MS). This study examined the time to first use of DMDs in newly diagnosed MS patients. METHODS In a post hoc analysis, newly diagnosed MS patients were identified using a national managed care database. Patients, aged 18 to 65 years, received their first MS diagnosis between July 1, 2000 and December 31, 2005 (index date), and were continuously eligible for 6 months prior to the index date and 24 months after the index date. During the 24-month postindex period, subjects received ≥1 DMD (interferon beta [IFNb]-1a intramuscular, IFNb-1b, glatiramer acetate, IFNb-1a subcutaneous, or natalizumab). The analysis did not include patients whose first DMD prescription was given after the study end date (December 31, 2007), or those who had used DMD in 6 months preceding their first MS diagnosis. RESULTS A total of 2522 MS patients (76.3% women) met the inclusion criteria for the study. The mean ± standard deviation patient age was 42.1±9.7 years. Most patients (47.9%) were from the Midwest, reflecting the national database sampling. The median time from first MS diagnosis to first DMD use was 61.0 days; mean time was 140.2±171.9 days. When the time to first treatment was examined in 30-day increments, the results showed that 27.8% received their first DMD in <30 days, 49.0% in <60 days, 59.6% in <90 days, and 74.2% in <180 days. One of every 4 patients (25.8%) did not initiate DMD for ≥180 days following their first diagnosis. CONCLUSIONS The findings of this analysis suggest that newly diagnosed MS patients often delay initiating DMD therapy.
Conference/Value in Health Info
2009-05, ISPOR 2009, Orlando, FL, USA
Value in Health, Vol. 12, No. 3 (May 2009)
Code
PND21
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
Neurological Disorders